Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access With Trappsol Cyclo for an Individual Patient With Late Onset Alzheimer's Disease

Trial Profile

Expanded Access With Trappsol Cyclo for an Individual Patient With Late Onset Alzheimer's Disease

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs Hydroxypropyl betadex (Primary)
  • Indications Alzheimer's disease
  • Focus Expanded access; Therapeutic Use
  • Sponsors CTD Holdings
  • Most Recent Events

    • 09 Oct 2018 According to a CTD Holdings media release, Dr. Hrynkow will describe its expanded access program approved by FDA in March 2018 to provide Trappsol Cyclo to a single patient with late-onset Alzheimers disease, at the annual BioFlorida Conference to be held on 15-17 Oct 2018 (Fort Lauderdale, Florida).
    • 20 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top